(Q72190826)
Statements
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone (English)
Adami S
Zamberlan N
Mian M
Dorizzi R
Rossini M
Braga B
Gatti D
Bertoldo F